Macrophage-Dendritic Cell-T-Cell Tetrads Orchestrate Antitumor Immunity and Response to Checkpoint Blockade
Abstract
Immune checkpoint inhibitors (ICIs) elicit durable responses in only a subset of patients with solid tumors, underscoring the need to define the cellular architectures that govern effective antitumor immunity. Here we identify a spatially organized multicellular immune unit comprising macrophages, cDC1s, CD4+ T-cells, and CD8+ T-cells that emerges in response to anti-CTLA-4 or dual checkpoint blockade. We term these structures tetrads. Using multiplexed imaging and spatial transcriptomics in mouse and human tumors, we show that tetrads assemble early during immune priming, depend on the ICOS-ICOSL pathway, and are enriched for ICOS+ Th1-like CD4+ T cells and ICOSL-high cDC1s. CD8+ T-cells within tetrads exhibit an activated, non-terminally differentiated state, while tetrad-associated macrophages display an interferon gamma-responsive program that sustains CD8+ T-cell function and prevents dysfunction. Functionally, ICOSL+ cDC1s are required for tumor eradication in vivo. In patients with bladder cancer treated with neoadjuvant dual checkpoint blockade, tetrad, but not triad or dyad formation correlates with clinical response. These findings establish tetrads as a fundamental cellular unit coordinating antitumor immunity and responsiveness to ICIs.
Links & Resources
Authors
Cite This Paper
M., C., M., A., S., H., M., A., Y., X., A., B., A., C., D., M. M., H., H. K., M., G., X., C., J., M. J., S., B., S., J., J., B., S., W., J., W., P., A. J., P., S. (2025). Macrophage-Dendritic Cell-T-Cell Tetrads Orchestrate Antitumor Immunity and Response to Checkpoint Blockade. arXiv preprint arXiv:10.64898/2025.12.24.696419.
Chaib, M., Aminu, M., Herbrich, S., Arabi, M., Xuan, Y., Basi, A., Casasent, A., Macaluso, M. D., Hu, K. H., Gubin, M., Chen, X., Mancuso, J. J., Basu, S., Jindal, S., Burks, J., Watowich, S., Wu, J., Allison, J. P., and Sharma, P.. "Macrophage-Dendritic Cell-T-Cell Tetrads Orchestrate Antitumor Immunity and Response to Checkpoint Blockade." arXiv preprint arXiv:10.64898/2025.12.24.696419 (2025).